Targeting lncRNA DDIT4‐AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy
Advanced Science · 2023-06 · 10 (17)
DOI: 10.1002/advs.202207257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.04.2023. Verfasst von Ting Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Postgraduate Research and Innovation Project of Central South University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
In this study, it is found that the lncRNA, DNA damage inducible transcript 4 antisense RNA1 (DDIT4‐AS1), is highly expressed in triple‐negative breast cancer (TNBC) cell lines and tissues due to H3K27 acetylation in the promoter region, and promotes the proliferation, migration, and invasion of TNBC cells via activating autophagy. Mechanistically, it is shown that DDIT4‐AS1 induces autophagy by stabilizing DDIT4 mRNA via recruiting the RNA binding protein AUF1 and promoting the interaction between DDIT4 mRNA and AUF1, thereby inhibiting mTOR signaling pathway. Furthermore, silencing of DDIT4‐AS1 enhances the sensitivity of TNBC cells to chemotherapeutic agents such as paclitaxel both in vitro and in vivo. Using a self‐activatable siRNA/drug core–shell nanoparticle system, which effectively deliver both DDIT4‐AS1 siRNA and paclitaxel to the tumor‐bearing mice, a significantly enhanced antitumor activity is achieved. Importantly, the codelivery nanoparticles exert a stronger antitumor effect on breast cancer patient‐derived organoids. These findings indicate that lncRNA DDIT4‐AS1‐mediated activation of autophagy promotes progression and chemoresistance of TNBC, and targeting of DDIT4‐AS1 may be exploited as a new therapeutic approach to enhancing the efficacy of chemotherapy against TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China.
- Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, 410011, China.
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine and Markey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
ORCID-Profile: Yan Cheng
Förderung
- National Natural Science Foundation of China
- Postgraduate Research and Innovation Project of Central South University
Zitieren
APA
Jiang, T., Zhu, J., Jiang, S., Chen, Z., Xu, P., Gong, R., Zhong, C., Cheng, Y., Sun, X., Yi, W., Yang, J., Zhou, W., & Cheng, Y. (2023). Targeting lncRNA DDIT4‐AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy. Advanced Science, 10(17). https://doi.org/10.1002/advs.202207257
Vancouver
Jiang T, Zhu J, Jiang S, Chen Z, Xu P, Gong R, et al. Targeting lncRNA DDIT4‐AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy. Advanced Science. 2023;10(17). doi:10.1002/advs.202207257
BibTeX
@article{Jiang2023,
author = {Jiang, Ting and Zhu, Jiaojiao and Jiang, Shilong and Chen, Zonglin and Xu, Ping and Gong, Rong and Zhong, Changxin and Cheng, Yueying and Sun, Xinyuan and Yi, Wenjun and Yang, Jinming and Zhou, Wenhu and Cheng, Yan},
title = {Targeting lncRNA DDIT4‐AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {17},
doi = {10.1002/advs.202207257}
}
EUVIMED